Literature DB >> 1529901

Circadian fluctuations of tissue plasminogen activator antigen and plasminogen activator inhibitor-1 antigens in vasospastic angina.

K Sakata1, T Hoshino, H Yoshida, N Ono, S Ohtani, S Yokoyama, N Mori, T Kaburagi, C Kurata, T Urano.   

Abstract

To elucidate the circadian variation of fibrinolytic components in vasospastic angina, plasma levels of tissue plasminogen activator antigen (t-PA), free plasminogen activator inhibitor antigen (free PAI-1), t-PA/PAI-1 complex, and total PAI-1 were measured in venous plasma samples. Samples were taken every 6 hours (6:00 AM, noon, 6:00 PM, and midnight) for 24 hours in 14 patients with vasospastic angina, in 9 patients with exertional angina, and in 19 normal subjects. Twenty-four-hour Holter monitoring (Holter monitor, Del Mar Avionics, Irvine, Calif.) was also carried out in all subjects. All of the fibrinolytic components showed circadian variation, with a peak level at 6:00 AM in every study group except for the t-PA/PAI-1 complex in the group of patients with exertional angina. The values for all or the fibrinolytic components at each sampling time were higher in patients with coronary artery disease than in normal subjects. In particular, the mean value of free PAI-1 at 6:00 AM in patients with vasospastic angina was significantly higher than that in normal subjects and that in patients with exertional angina. This value of free PAI-1 in patients with vasospastic angina was closely associated with the duration of ischemic attacks. These results suggested that the circadian fluctuation of fibrinolytic components may be an important factor that leads to coronary thrombosis at the time of coronary spasm, especially in the early morning.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1529901     DOI: 10.1016/0002-8703(92)90964-w

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Multifocal spasm with acetylcholine in Prinzmetal angina.

Authors:  H R Michels; H F Baars
Journal:  Neth Heart J       Date:  2008-04       Impact factor: 2.380

2.  Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study.

Authors:  Thomas Walter; Sebastian Szabo; Tim Suselbeck; Martin Borggrefe; Siegfried Lang; Stefanie Swoboda; Hans Martin Hoffmeister; Carl-Erik Dempfle
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina.

Authors:  K Sakata; T Hoshino; H Yoshida; T Kaburagi; A Takada
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

4.  Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism.

Authors:  Tobias Frischmuth; Kristian Hindberg; Pål Aukrust; Thor Ueland; Sigrid K Braekkan; John-Bjarne Hansen; Vânia M Morelli
Journal:  J Thromb Haemost       Date:  2022-03-25       Impact factor: 16.036

Review 5.  Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions.

Authors:  Simon C Dyall; Laurence Balas; Nicolas G Bazan; J Thomas Brenna; Nan Chiang; Felipe da Costa Souza; Jesmond Dalli; Thierry Durand; Jean-Marie Galano; Pamela J Lein; Charles N Serhan; Ameer Y Taha
Journal:  Prog Lipid Res       Date:  2022-05-01       Impact factor: 14.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.